Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | TIMP3 | P35625 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7699608 | 0.74 | MEN1 (0.40) | CYP3A4TSHRRECQLLMNACA12 | |
| SCHEMBL15325422 | 0.73 | ALDH1A1 (0.46) | TSHRRECQLLMNACASP6CA12 | |
| SCHEMBL6660835 | 0.72 | CYP3A4 (0.56) | CYP3A4TSHRRECQLLMNACASP6 | |
| SCHEMBL9327344 | 0.72 | LMNA (0.44) | CYP3A4TSHRRECQLLMNACASP6 | |
| SCHEMBL9329057 | 0.72 | TIMP3 (0.48) | RECQLLMNACASP6CA12CA1 | |
| SCHEMBL8619918 | 0.72 | CYP3A4 (0.43) | CYP3A4TSHRRECQLLMNACASP6 | |
| SCHEMBL16490263 | 0.72 | MEN1 (0.39) | CYP3A4TSHRRECQLCA12CA1 | |
| SCHEMBL1263804 | 0.71 | CYP2C9 (0.38) | CYP3A4TSHRRECQLLMNA | |
| SCHEMBL15133691 | 0.71 | CYP2C9 (0.39) | CYP3A4TSHRRECQL | |
| SCHEMBL6402835 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| WO-2014200872-A9 | PHARMACEUTICAL COMPOUNDS TARGETED BY MIF AFFINITY-TETHERED MOIETIES | RJS BIOLOGICS LLC (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014200872-A1 | PHARMACEUTICAL COMPOUNDS TARGETED BY MIF AFFINITY-TETHERED MOIETIES | RJS BIOLOGICS LLC (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | MIF, HMGB2, HMGB1 | CYP3A4 2877/4885TSHR 3054/4885RECQL 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.